KeyZell revolutionizes the fight against lung and breast cancer with an Artificial Intelligence tool

The Spanish biotechnology startup KeyZell, in alliance with the technology company Iakan, has presented an Artificial Intelligence solution capable of recommending personalized treatments for lung and breast cancer to medical professionals, taking into account the individual characteristics of each patient and their type of cancer.

MADRID, 10 (MEDIA SERVICE)

The Spanish biotechnology startup KeyZell, in alliance with the technology company Iakan, has presented an Artificial Intelligence solution capable of recommending personalized treatments for lung and breast cancer to medical professionals, taking into account the individual characteristics of each patient and their type of cancer.

The company noted that Keyzell OPS helps oncologists make more accurate decisions by enabling personalized medicine, reducing recurrence, overmedication, hospitalization time, treatment costs, follow-up through all clinical phases, and , above all, has a positive impact on the quality of life of patients.

In this sense, he stressed that currently health professionals are forced to make decisions “with a high level of uncertainty”, since each patient may have a different response to treatment. In addition, current protocols involve high levels of toxicity, “which increases the suffering and side effects of those affected, being key to personalize treatments as much as possible and to know their level of effectiveness in each case.”

Keyzell OPS is based on a ‘machine learning’ system in continuous learning, which feeds on thousands of data from medical records, creating machine learning models from the medical experience collected over the years, “which was wasted given the difficulty of managing such a volume of data effectively, in order to optimize decision making”.

The company emphasizes that the use of this system also speeds up response times for patients, since it has a positive impact on oncologists’ management times, increases the quality of follow-up and allows complications to be dealt with quickly, improving personalized patient care . “The oncologist simply enters the patient’s data on the platform and it breaks down the most suitable treatments for him in the form of a ranking.”

OPS, whose industrial property has been obtained thanks to the Keyzell team, has been trained with the help of lakan technology from millions of data on cancer, from different cohorts around the world. Keyzell OPS has been “trained” with over 100,000 records. It includes recognition of diagnostic images and considers more than 30 variables of clinical data, ranging from data on the tumor, organ, state, together with the sequencing reading with biomarkers, among others, which makes it possible to predict which drug and/or combination of drugs with the highest success rate.

Currently, it is available for breast cancer and lung cancer. In the first case, it is a ‘machine learning’ model for predicting survival created from breast cancer registries of patients in the US and at the Puebla Hospital in Mexico; and, in the second, an effectiveness and toxicity prediction model, with lung cancer registries from hospitals in Spain.

In addition, KeyZell has several lines of research and training open for other types of cancer, and is developing an even more advanced version of Keyzell OPS for multi-omic precision medicine, with a security model based on Blockchain technology.

(SERVIMEDIA) 10-MAY-2022 14:09 (GMT +2) S/gja

© SERVIMEDIA. This information is property of Servimedia. It can only be disseminated by the clients of this news agency citing Servimedia as author or source. All rights reserved. Distribution and public communication by third parties by any means or support is prohibited.

See here the complete article of La Vanguardia.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Recent news

Follow us on the networks

Subscribe to our newsletters

You will only receive notifications about new news and updates.

More news

The BME Pre Market Environment welcomes KeyZell, Pharmamel y OpenWebinars and reaches 25 companies

The Pre Market Environemnt (EpM), the BME acceleration program for the incorporation of companies into the financial markets, welcomes three new companies: KeyZell, Pharmamel and ...
Read more →
Premios EmprendeXXI de CaixaBank

KeyZell finalist in CaixaBank’s Emprende XXI Awards

KeyZell, a company dedicated to the development of artificial intelligence technology applied to cancer, has been selected as a finalist in the EmprendeXXI Awards. These ...
Read more →

KeyZell participates as a reference in biotechnology in the new edition of MAD e-Health

KeyZell has been one of the companies invited to participate on April 28th in the Madrid Capital e-Health cluster (link). The event aims to bring ...
Read more →

KeyZell awarded with the Andalucía Excelente prize, best Biotechnology company 2022.

KeyZell received the Andalucía Excelente Award as the best Biotechnology company 2022. KeyZell, awarded for its commitment to create a new future for oncology, through ...
Read more →

Comitas e-health and Keyzell implement an AI solution for the early detection of lung and breast cancer

Comitas e-health and the Andalusian company Keyzell have formalized an alliance for the development of an innovative telemedicine solution for the early diagnosis and treatment ...
Read more →

KeyZell develops the first precision medicine system to fight breast and lung cancer

The startup has developed the first oncology precision medicine system that selects “personalized treatment for each patient.”- Seguir leyendo:https://www.libertaddigital.com/ciencia-tecnologia/salud/2022-10-14/keyzell-desarrolla-el-primer-sistema-de-medicina-de-precision-para-combatir-el-cancer-de-mama-y-pulmon-6942968/   As explained by the company ...
Read more →

Fourier Intelligence, iRhythm and KeyZell are the most internationally recognized companies for revolutionizing the health sector

Health Tech World has released a compilation of the top 50 health technology innovators of 2022 who stand out for their unique innovation, outstanding technology ...
Read more →

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe”

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe” in the seventh edition of the “International Life Sciences Awards 2022“. This event ...
Read more →

KeyZell continues to advance in the development of its Artificial Intelligence tool

The biotech startup KeyZell has officially announced the launch of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for precision medicine ...
Read more →